Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. Lawsuit

Core Viewpoint - A class action securities lawsuit has been filed against Humacyte, Inc. due to alleged securities fraud affecting investors between May 10, 2024, and October 17, 2024 [1] Group 1: Allegations - The lawsuit claims that Humacyte's facility in Durham, North Carolina did not comply with good manufacturing practices, including quality assurance and microbial testing [2] - It is alleged that the FDA's review of Humacyte's biologics license application would be delayed while the company addressed these deficiencies [2] - There is a substantial risk to the FDA approval of Humacyte's acellular tissue engineered vessel for vascular trauma as a result of these issues [2] - The defendants' positive statements regarding the company's business and prospects were misleading and lacked a reasonable basis [2] Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until January 17, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [4]